, Tracking Stock Market Picks
Enter Symbol:
Sarepta Therapeutics Inc (SRPT) [hlAlert]

Mkt Outperform
up 20.80 %

Sarepta Therapeutics Inc (SRPT) rated Mkt Outperform with price target $39 by Burrill Institutional Research

Posted on: Friday,  Mar 8, 2013  8:25 AM ET by Burrill Institutional Research

Burrill Institutional Research rated Mkt Outperform Sarepta Therapeutics Inc (NASDAQ: SRPT) on 03/08/2013. Previously Burrill Institutional Research rated Mkt Outperform Sarepta Therapeutics Inc (NASDAQ:
SRPT) on 11/26/2012., when the stock price was $29.99. Since then, Sarepta Therapeutics Inc has gained 20.81% as of 01/19/2016's recent price of $36.23.
If you would have followed the previous Burrill Institutional Research's recommendation on SRPT, you would have gained 20.8% of your investment in 1149 days.

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

Burrill Institutional Research
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/8/2013 8:25 AM Buy
30.25 39.00
as of 12/13/2013
1 Week up  9.18 %
1 Month up  53.06 %
3 Months down  -46.97 %
1 YTD down  -23.52 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/26/2012 8:25 AM Buy
29.99 54.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy